MedTrace Logo

TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)

NCT04405271 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1378

Last updated 2025-09-09

No results posted yet for this study

Summary

A randomized parallel double-blinded placebo-controlled clinical trial to evaluate the effect of Emtricitabine/Tenofovir alafenamide (FTC/TAF) compared with placebo on the risk of developing SARS-CoV-2 disease (COVID-19) in healthcare workers with high transmission risk in addition to currently recommended control measures.

Conditions

  • Healthcare Workers
  • COVID-19
  • SARS-CoV 2

Interventions

DRUG

Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet

Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks

DRUG

Placebo

A dose of 1 tablet per day will be administered for a total of 12 weeks.

Sponsors & Collaborators

  • Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)

    collaborator UNKNOWN

  • Hospital Italiano de Buenos Aires

    lead OTHER

Principal Investigators

  • Waldo H Belloso, MD · Hospital Italiano de Buenos Aires

  • Ventura Simonovich, MD · HIBA

  • Esteban Nannini, MD · Sanatorio Britanico

  • Wanda Cornistein, MD · Hospital Austral

  • Marcelo Figueiras, MD · Richmond Laboratorio

  • Elvira Zini, MD · Richmond Laboratorio

  • Fernando Riera, MD · Sanatorio Allende (Córdoba)

  • Omar Sued, MD · HUESPED

  • Santiago Ramirez Borga, MD · Hospital Italiano de La Plata

  • Gustavo Costilla Campero, MD · Hospital Padilla (Tucumán)

  • Gustavo D Lopardo, MD · Hospital Bernardo Houssay

  • Gonzalo Corral, MD · Hospital Alende (Mar del Plata)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2020-11-15
Completion
2020-11-15

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405271 on ClinicalTrials.gov